# US 2019/0315867 A1 · Anti-tigit antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315867 A1
- Document ID: US20190315867A1
- Status: Published application
- Kind: A1
- Application number: 16/413,557
- Filed: 2019-05-15
- Published: 2019-10-17
- Earliest claimed: 2017-07-27
- Assignees: Iteos Therapeutics
- Applicants: iTeos Therapeutics SA
- Inventors: Anthony Cooper; Christophe Queva; Sofie Denies; Catherine Hoofd; Julia Cuende; Gregory Driessens; Florence Lambolez
- Web page: https://patentgrep.com/patent/US20190315867A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 39/39541: {against normal tissues, cells}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2821: {against ICAM molecules, e.g. CD50, CD54, CD102}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/4208: {against an idiotypic determinant on Ig}
- C12N 15/85: for animal cells
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.

## Claims

### Claim 1

A method for treating cancer, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising an isolated antibody or antigen binding fragment thereof which binds to a human T cell Immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody or antigen binding fragment comprises a HCDR1, a HCDR2, a HCDR3, a LCDR1, a LCDR2 and a LCDR3, wherein:
(i) the HCDR1 comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 4; SEQ ID NO: 7; SEQ ID NO: 10; SEQ ID NO: 13; SEQ ID NO: 16; SEQ ID NO: 19; SEQ ID NO: 22; SEQ ID NO: 25; SEQ ID NO: 28; SEQ ID NO: 31; SEQ ID NO: 34; SEQ ID NO: 37: SEQ ID NO: 40; SEQ ID NO: 43; SEQ ID NO: 271; SEQ ID NO: 274; SEQ ID NO: 277; SEQ ID NO: 280; and SEQ ID NO: 33;
(ii) the HCDR2 comprises a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO: 5; SEQ ID NO: 8; SEQ ID NO: 11; SEQ ID NO: 14; SEQ ID NO: 17; SEQ ID NO: 20; SEQ ID NO: 23; SEQ ID NO: 26; SEQ ID NO: 29; SEQ ID NO: 32; SEQ ID NO: 35: SEQ ID NO: 38; SEQ ID NO: 41; SEQ ID NO: 44; SEQ ID NO: 272; SEQ ID NO: 275; SEQ ID NO: 278; SEQ ID NO: 281; and SEQ ID NO: 354;
(iii) the HCDR3 comprises a sequence selected from the group consisting of SEQ ID NO: 3; SEQ ID NO: 6; SEQ ID NO: 9; SEQ ID NO: 12; SEQ ID NO: 15; SEQ ID NO: 18; SEQ ID NO: 21; SEQ ID NO: 24; SEQ ID NO: 27; SEQ ID NO: 30; SEQ ID NO: 33; SEQ ID NO: 36; SEQ ID NO: 39: SEQ ID NO: 42; SEQ ID NO: 45; SEQ ID NO: 273; SEQ ID NO: 276; SEQ ID NO: 279; SEQ ID NO: 282; and SEQ ID NO: 355;
(iv) the LCDR1 comprises a sequence selected from the group consisting of SEQ ID NO: 46; SEQ ID NO: 49; SEQ ID NO: 52; SEQ ID NO: 55; SEQ ID NO: 58; SEQ ID NO: 61; SEQ ID NO: 64; SEQ ID NO: 67; SEQ ID NO: 70; SEQ ID NO: 73; SEQ ID NO: 76; SEQ ID NO: 79: SEQ ID NO: 82; SEQ ID NO: 85; SEQ ID NO: 88; SEQ ID NO: 283; SEQ ID NO: 286; SEQ ID NO: 289; SEQ ID NO: 292; and SEQ ID NO: 356;
(v) the LCDR2 comprises a sequence selected from the group consisting of SEQ ID NO: 47; SEQ ID NO: 50, SEQ ID NO: 53; SEQ ID NO: 56; SEQ ID NO: 59; SEQ ID NO: 62; SEQ ID NO: 65; SEQ ID NO: 68; SEQ ID NO: 71; SEQ ID NO: 74; SEQ ID NO: 77; SEQ ID NO: 80; SEQ ID NO: 83: SEQ ID NO: 86; SEQ ID NO: 89; SEQ ID NO: 284; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 293; and SEQ ID NO: 357; and
(vi) the LCDR3 comprises a sequence selected from the group consisting of SEQ ID NO: 48; SEQ ID NO: 51; SEQ ID NO: 54; SEQ ID NO: 57; SEQ ID NO: 60; SEQ ID NO: 63; SEQ ID NO: 66; SEQ ID NO: 69; SEQ ID NO: 72; SEQ ID NO: 75; SEQ ID NO: 78; SEQ ID NO: 81; SEQ ID NO: 84: SEQ ID NO: 87; SEQ ID NO: 90; SEQ ID NO: 285; SEQ ID NO: 288; SEQ ID NO: 291; SEQ ID NO: 294; and SEQ ID NO: 358.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method further comprises administration of one or more additional therapeutic agents, wherein the one or more therapeutic agents is selected from: a chemotherapeutic agent, an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41BB antibody, an anti-OX40 antibody, an anti-GITR antibody, and an anti-ICOS antibody, wherein the efficacy of the method of treatment is greater than the efficacy of method of treatment with the pharmaceutical composition alone or with the additional therapeutic agent alone.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the method further comprises administration of one or more additional therapeutic agents, wherein the one or more therapeutic agent is selected from: an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41BB antibody, an anti-OX40 antibody, an anti-GITR antibody, and an anti-ICOS antibody, wherein the administration to the patient of the pharmaceutical composition and the additional therapeutic agent results in synergistic anti-tumor efficacy compared to either the pharmaceutical composition or the additional therapeutic agent alone.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the isolated antibody or antigen binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises SEQ ID NO: 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 239, 327, 329, or 331 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% sequence identity thereto, and the light chain variable domain comprises SEQ ID NO: 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 328, 330, or 332 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% sequence identity thereto.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the isolated antibody or antigen binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises SEQ ID NO: 219 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical to SEQ ID NO: 219, and the light chain variable domain comprises the amino acid sequence shown as SEQ ID NO: 220 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% identical to SEQ ID NO: 220.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the isolated antibody or antigen-binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises SEQ ID NO: 221 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical to SEQ ID NO:221, and the light chain variable domain comprises SEQ ID NO: 222 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical to SEQ ID NO:22.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the antibody or antigen binding fragment is a human IgG antibody or a human IgG1 antibody.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the effective amount of the pharmaceutical composition is effective for selective depletion of TIGIT-expressing T-regulatory (T-reg) cells in the subject, compared to a control.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the effective amount of the pharmaceutical composition is effective for decreasing expression and/or inhibitory activity of TIGIT on CD8 T cells and/or on T-reg cells in the subject, compared to a control.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the HCDR1 comprises SEQ ID NO: 16 (YTFTSYYMH), HCDR2 comprises SEQ ID NO: 17 (VIGPSGASTSYAQKFQG), HCDR3 comprises SEQ ID NO: 18 (ARDHSDYWSGIMEV), LCDR1 comprises SEQ ID NO: 61 (RASQSVRSSYLA), LCDR2 comprises SEQ ID NO: 62 (GASSRAT), and LCDR3 comprises SEQ ID NO: 63 (QQYFSPPWT).

### Claim 11

A method for increasing patient survival, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising an isolated antibody or antigen binding fragment thereof which binds to a human T cell Immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody or antigen binding fragment comprises a combination of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein:
(i) The HCDR1 comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 4; SEQ ID NO: 7; SEQ ID NO: 10; SEQ ID NO: 13; SEQ ID NO: 16; SEQ ID NO: 19; SEQ ID NO: 22; SEQ ID NO: 25; SEQ ID NO: 28; SEQ ID NO: 31; SEQ ID NO: 34; SEQ ID NO: 37: SEQ ID NO: 40; SEQ ID NO: 43; SEQ ID NO: 271; SEQ ID NO: 274; SEQ ID NO: 277; SEQ ID NO: 280; SEQ ID NO: 33;
(ii) The HCDR2 comprises a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO: 5; SEQ ID NO: 8; SEQ ID NO: 11; SEQ ID NO: 14; SEQ ID NO: 17; SEQ ID NO: 20; SEQ ID NO: 23; SEQ ID NO: 26; SEQ ID NO: 29; SEQ ID NO: 32; SEQ ID NO: 35: SEQ ID NO: 38; SEQ ID NO: 41; SEQ ID NO: 44; SEQ ID NO: 272; SEQ ID NO: 275; SEQ ID NO: 278; SEQ ID NO: 281; SEQ ID NO: 354;
(iii) The HCDR3 comprises a sequence selected from the group consisting of SEQ ID NO: 3; SEQ ID NO: 6; SEQ ID NO: 9; SEQ ID NO: 12; SEQ ID NO: 15; SEQ ID NO: 18; SEQ ID NO: 21; SEQ ID NO: 24; SEQ ID NO: 27; SEQ ID NO: 30; SEQ ID NO: 33; SEQ ID NO: 36; SEQ ID NO: 39: SEQ ID NO: 42; SEQ ID NO: 45; SEQ ID NO: 273; SEQ ID NO: 276; SEQ ID NO: 279; SEQ ID NO: 282; SEQ ID NO: 355;
(iv) The LCDR1 comprises a sequence selected from the group consisting of SEQ ID NO: 46; SEQ ID NO: 49; SEQ ID NO: 52; SEQ ID NO: 55; SEQ ID NO: 58; SEQ ID NO: 61; SEQ ID NO: 64; SEQ ID NO: 67; SEQ ID NO: 70; SEQ ID NO: 73; SEQ ID NO: 76; SEQ ID NO: 79: SEQ ID NO: 82; SEQ ID NO: 85; SEQ ID NO: 88; SEQ ID NO: 283; SEQ ID NO: 286; SEQ ID NO: 289; SEQ ID NO: 292; SEQ ID NO: 356;
(v) The LCDR2 comprises a sequence selected from the group consisting of SEQ ID NO: 47; SEQ ID NO: 50, SEQ ID NO: 53; SEQ ID NO: 56; SEQ ID NO: 59; SEQ ID NO: 62; SEQ ID NO: 65; SEQ ID NO: 68; SEQ ID NO: 71; SEQ ID NO: 74; SEQ ID NO: 77; SEQ ID NO: 80; SEQ ID NO: 83: SEQ ID NO: 86; SEQ ID NO: 89; SEQ ID NO: 284; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 293; SEQ ID NO: 357; and
(vi) The LCDR3 comprises a sequence selected from the group consisting of SEQ ID NO: 48; SEQ ID NO: 51; SEQ ID NO: 54; SEQ ID NO: 57; SEQ ID NO: 60; SEQ ID NO: 63; SEQ ID NO: 66; SEQ ID NO: 69; SEQ ID NO: 72; SEQ ID NO: 75; SEQ ID NO: 78; SEQ ID NO: 81; SEQ ID NO: 84: SEQ ID NO: 87; SEQ ID NO: 90; SEQ ID NO: 285; SEQ ID NO: 288; SEQ ID NO: 291; SEQ ID NO: 294; SEQ ID NO: 358.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the method further comprises administration of an effective amount of one or more additional therapeutic agent, wherein the one or more therapeutic agent is selected from: a chemotherapeutic agent, an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41 BB antibody, an anti-OX40 antibody, an anti-GITR antibody, and an anti-ICOS antibody, wherein the efficacy of the treatment is greater than the efficacy of treatment with the pharmaceutical composition alone or with the additional therapeutic agent alone.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the isolated antibody or antigen binding fragment comprises a combination of a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises SEQ ID NO: 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 239, 327, 329, or 331 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical thereto, and the light chain variable domain comprises SEQ ID NO: 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 328, 330, or 332 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical thereto.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the isolated antibody or antigen binding fragment comprises a combination of a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises SEQ ID NO: 219 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical thereto, and the light chain variable domain comprises SEQ ID NO: 220 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical thereto.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the isolated antibody or antigen-binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises SEQ ID NO: 221 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical to SEQ ID NO:221, and the light chain variable domain comprises SEQ ID NO: 222 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical to SEQ ID NO:22.

### Claim 16

A method for reducing tumor volume, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising
i) an isolated antibody or antigen binding fragment thereof which binds to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody or antigen binding fragment comprises a HCDR1, a HCDR2, a HCDR3, a LCDR1, a LCDR2 and a LCDR3, wherein:
(i) The HCDR1 comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 4; SEQ ID NO: 7; SEQ ID NO: 10; SEQ ID NO: 13; SEQ ID NO: 16; SEQ ID NO: 19; SEQ ID NO: 22; SEQ ID NO: 25; SEQ ID NO: 28; SEQ ID NO: 31; SEQ ID NO: 34; SEQ ID NO: 37: SEQ ID NO: 40; SEQ ID NO: 43; SEQ ID NO: 271; SEQ ID NO: 274; SEQ ID NO: 277; SEQ ID NO: 280; SEQ ID NO: 33;
(ii) The HCDR2 comprises a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO: 5; SEQ ID NO: 8; SEQ ID NO: 11; SEQ ID NO: 14; SEQ ID NO: 17; SEQ ID NO: 20; SEQ ID NO: 23; SEQ ID NO: 26; SEQ ID NO: 29; SEQ ID NO: 32; SEQ ID NO: 35: SEQ ID NO: 38; SEQ ID NO: 41; SEQ ID NO: 44; SEQ ID NO: 272; SEQ ID NO: 275; SEQ ID NO: 278; SEQ ID NO: 281; SEQ ID NO: 354;
(iii) The HCDR3 comprises a sequence selected from the group consisting of SEQ ID NO: 3; SEQ ID NO: 6; SEQ ID NO: 9; SEQ ID NO: 12; SEQ ID NO: 15; SEQ ID NO: 18; SEQ ID NO: 21; SEQ ID NO: 24; SEQ ID NO: 27; SEQ ID NO: 30; SEQ ID NO: 33; SEQ ID NO: 36; SEQ ID NO: 39: SEQ ID NO: 42; SEQ ID NO: 45; SEQ ID NO: 273; SEQ ID NO: 276; SEQ ID NO: 279; SEQ ID NO: 282; SEQ ID NO: 355;
(iv) The LCDR1 comprises a sequence selected from the group consisting of SEQ ID NO: 46; SEQ ID NO: 49; SEQ ID NO: 52; SEQ ID NO: 55; SEQ ID NO: 58; SEQ ID NO: 61; SEQ ID NO: 64; SEQ ID NO: 67; SEQ ID NO: 70; SEQ ID NO: 73; SEQ ID NO: 76; SEQ ID NO: 79: SEQ ID NO: 82; SEQ ID NO: 85; SEQ ID NO: 88; SEQ ID NO: 283; SEQ ID NO: 286; SEQ ID NO: 289; SEQ ID NO: 292; SEQ ID NO: 356;
(v) The LCDR2 comprises a sequence selected from the group consisting of SEQ ID NO: 47; SEQ ID NO: 50, SEQ ID NO: 53; SEQ ID NO: 56; SEQ ID NO: 59; SEQ ID NO: 62; SEQ ID NO: 65; SEQ ID NO: 68; SEQ ID NO: 71; SEQ ID NO: 74; SEQ ID NO: 77; SEQ ID NO: 80; SEQ ID NO: 83: SEQ ID NO: 86; SEQ ID NO: 89; SEQ ID NO: 284; SEQ ID NO: 287; SEQ ID NO: 290; SEQ ID NO: 293; SEQ ID NO: 357; and
(vi) the LCDR3 comprises a sequence selected from the group consisting of SEQ ID NO: 48; SEQ ID NO: 51; SEQ ID NO: 54; SEQ ID NO: 57; SEQ ID NO: 60; SEQ ID NO: 63; SEQ ID NO: 66; SEQ ID NO: 69; SEQ ID NO: 72; SEQ ID NO: 75; SEQ ID NO: 78; SEQ ID NO: 81; SEQ ID NO: 84: SEQ ID NO: 87; SEQ ID NO: 90; SEQ ID NO: 285; SEQ ID NO: 288; SEQ ID NO: 291; SEQ ID NO: 294; SEQ ID NO: 358, and
(vii) an effective amount of one or more additional therapeutic agents, wherein the one or more therapeutic agents is selected from: a chemotherapeutic agent, an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-41BB antibody, an anti-OX40 antibody, an anti-GITR antibody, and an anti-ICOS antibody wherein the efficacy of the method of treatment is greater than the efficacy of method of treatment with the pharmaceutical composition alone or with the additional therapeutic agent alone.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the HCDR1 comprises SEQ ID NO: 16 (YTFTSYYMH), HCDR2 comprises SEQ ID NO: 17 (VIGPSGASTSYAQKFQG), HCDR3 comprises SEQ ID NO: 18 (ARDHSDYWSGIMEV), LCDR1 comprises SEQ ID NO: 61 (RASQSVRSSYLA), LCDR2 comprises SEQ ID NO: 62 (GASSRAT), and LCDR3 comprises SEQ ID NO: 63 (QQYFSPPWT).

### Claim 18 (depends on 16)

The method according to claim 16, wherein the isolated antibody or antigen binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises SEQ ID NO: 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 239, 327, 329, or 331 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical thereto, and the light chain variable domain comprises SEQ ID NO: 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 328, 330, or 332 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical thereto.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the isolated antibody or antigen binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises SEQ ID NO: 219 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical to SEQ ID NO: 219, and the light chain variable domain comprises the amino acid sequence shown as SEQ ID NO: 220 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98% or 99% identical to SEQ ID NO: 220.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the isolated antibody or antigen-binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises SEQ ID NO: 221 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical to SEQ ID NO:221, and the light chain variable domain comprises SEQ ID NO: 222 or an amino acid sequence at least 90%, 95%, 97%, 98% or 99% identical to SEQ ID NO:22.
